Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.68 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1039673 | 0.99 | DRD2 (0.69) | DRD2HRH3 | |
| Hydrochloric Acid SCHEMBL5510076 | 0.98 | DRD2 (0.66) | DRD2HRH3 | |
| Hydrochloric Acid SCHEMBL5510074 | 0.97 | DRD2 (0.65) | DRD2HRH3 | |
| Hydrochloric Acid SCHEMBL293576 | 0.95 | DRD2 (0.75) | DRD2 | |
| SCHEMBL1038131 | 0.93 | DRD2 (0.70) | DRD2HRH3 | |
| Hydrochloric Acid SCHEMBL293811 | 0.85 | DRD2 (0.62) | DRD2 | |
| Hydrochloric Acid SCHEMBL299134 | 0.85 | DRD2 (0.62) | DRD2HRH3 | |
| Hydrochloric Acid SCHEMBL1035583 | 0.85 | DRD2 (0.72) | DRD2 | |
| Hydrochloric Acid SCHEMBL510767 | 0.84 | DRD2 (0.61) | DRD2HRH3 | |
| SCHEMBL1037458 | 0.84 | DRD2 (0.73) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-22 | — | — | US | disclosed |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-07-30 | — | — | US | disclosed |
| US-RE48059-E1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9839637-B1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-12-12 | — | — | US | disclosed |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20170000786-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-01-05 | — | — | US | disclosed |
| US-20160051548-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-02-25 | — | — | US | disclosed |
| US-9206167-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20140163039-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-06-12 | — | — | US | disclosed |
| US-8618109-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PARMACEUTICAL CO., LTD. (JP) | 2013-12-31 | — | — | US | disclosed |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-20 | — | — | US | disclosed |
| US-8349840-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-06-23 | — | — | US | disclosed |
| US-7888362-B2 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-15 | — | — | US | disclosed |
| EP-1869025-B1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMA CO LTD (JP) | 2011-01-26 | — | — | EP | disclosed |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368060-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20100179322-A1 | Piperazine-substituted benzothiophenes for treatment of mental disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20200237755-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20190117648-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20140163039-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20130158044-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20170000786-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20180214444-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20170231983-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20210113556-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20160051548-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20110152286-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
| US-20190321359-A1 | Piperazine-Substituted Benzothiophenes For Treatment of Mental Disorders | GRIN2C, TPH1, HTR2C | DRD2 126/4885HRH3 1511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.